Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see additional presentation details below:
H.C. Wainwright Global Investment Conference (Hybrid Conference)
- Speaker: Dr. Linda Marbán, CEO of Capricor
- Date and Time: Wednesday, May 25, 2022 at 9:30 a.m. ET
- Webcast: Registration Link – Click Here
The presentation link will also be available in the events section of the Capricor website.
In addition, the Company will be available for one-on-one meetings during the conference. Registered investors will be able to request a meeting via the conference portal.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor`s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA as well as proteins, to treat or prevent a variety of diseases.